Javascript must be enabled to continue!
e0033 Mechanisms of losartan attenuates ventricular remodelling and cardiac function in aortic banded rats with chronic heart failure
View through CrossRef
Objective
To investigate the regulation of Losartan (Los) on ventricular remodelling and cardiac functioning chronic heart failure rats induced by aortic banded.
Methods
Sprague-Dawley (SD) rats underwent abdominal aorta coarctation to induce CHF, confirmed by ultrasound cardiograph and Catheterisation, or sham operation, followed by 8 weeks treatment with Losartan (20 mg/kg per day, orally) or vehicle (drinking water). Plasma norepinephrine (NE) was measured by ELISA, and plasma and tissue angiotensin II (Ang II) levels were measured using RIA. Cardiomyocyte apoptosis was examined by agarose gel electrophoresis and TUNEL's method. The mRNA levels of Bax and Bcl-2 were determined by RT-PCR and the protein expression of phosphorylated and total Akt(t-Akt and p-Akt) were assessed by Western blot.
Results
Losartan-treated CHF rats had lower left ventricular end-diastolic pressure (LVEDP) [COA+Los: (11.47±5.06) mm Hg vs COA+Vehicle: (21.18±6.56) mm Hg, p<0.01], higher left ventricular ejection fraction (LVEF) [COA+Los: (63.28±4.32)% vs COA+Vehicle: (43.27±4.25)%, p<0.05]and lower left ventricle/body weight ratios [COA+Los: (2.41±0.15) mg/g vs COA+ Vehicle: (3.12±0.18) mg/g, p<0.05], lower plasma NE[COA+Los: (682.24±64.66) pg/ml vs COA+ Vehicle : (908.24±75.10) pg/ml, p<0.05] and myocardium Ang II[COA+Los : (60.15±6.22) pg/mgprot vs COA+ Vehicle : (92.31±8.31) pg/mgprot, p<0.05], but higher plasma Ang II[COA+Los : (629.68±85.71) pg/ml vs COA+ Vehicle : (475.67±51.12) pg/ml, p<0.05] than vehicle-treated CHF rats. Losartan-treated HF rats had no obviously “DNA ladder” which was the character of apoptosis, and the apoptosis index was also reduced [COA+Los: (5.49±0.45)% vs COA+Vehicle: (9.62±0.51)%, p<0.05] with a lower express of Bax/Bcl-2 gene [COA+Los: (109.58±7.53)% vs COA+Vehicle: (136.76±8.82)%, p<0.05] and a higher protein expression of p-Akt[COA+Los: (70.80±6.40)% vs COA+Vehicle: (50.30±4.80)%, p<0.05].
Conclusion
Losartan might inhibit cardiomyocyte apoptosis and improve cardiac function in aortic banded rats by blocking Ang II to bind AT1-R and promoting the activation of Akt.
Conclusion
Los attenuated ventricular remodelling and improve cardiac function in aortic banded rats by blocking angiotensin II to bind AT1-R and reducing angiotensin II, aldosterone and inflammatory cytokine in myocardium.
Title: e0033 Mechanisms of losartan attenuates ventricular remodelling and cardiac function in aortic banded rats with chronic heart failure
Description:
Objective
To investigate the regulation of Losartan (Los) on ventricular remodelling and cardiac functioning chronic heart failure rats induced by aortic banded.
Methods
Sprague-Dawley (SD) rats underwent abdominal aorta coarctation to induce CHF, confirmed by ultrasound cardiograph and Catheterisation, or sham operation, followed by 8 weeks treatment with Losartan (20 mg/kg per day, orally) or vehicle (drinking water).
Plasma norepinephrine (NE) was measured by ELISA, and plasma and tissue angiotensin II (Ang II) levels were measured using RIA.
Cardiomyocyte apoptosis was examined by agarose gel electrophoresis and TUNEL's method.
The mRNA levels of Bax and Bcl-2 were determined by RT-PCR and the protein expression of phosphorylated and total Akt(t-Akt and p-Akt) were assessed by Western blot.
Results
Losartan-treated CHF rats had lower left ventricular end-diastolic pressure (LVEDP) [COA+Los: (11.
47±5.
06) mm Hg vs COA+Vehicle: (21.
18±6.
56) mm Hg, p<0.
01], higher left ventricular ejection fraction (LVEF) [COA+Los: (63.
28±4.
32)% vs COA+Vehicle: (43.
27±4.
25)%, p<0.
05]and lower left ventricle/body weight ratios [COA+Los: (2.
41±0.
15) mg/g vs COA+ Vehicle: (3.
12±0.
18) mg/g, p<0.
05], lower plasma NE[COA+Los: (682.
24±64.
66) pg/ml vs COA+ Vehicle : (908.
24±75.
10) pg/ml, p<0.
05] and myocardium Ang II[COA+Los : (60.
15±6.
22) pg/mgprot vs COA+ Vehicle : (92.
31±8.
31) pg/mgprot, p<0.
05], but higher plasma Ang II[COA+Los : (629.
68±85.
71) pg/ml vs COA+ Vehicle : (475.
67±51.
12) pg/ml, p<0.
05] than vehicle-treated CHF rats.
Losartan-treated HF rats had no obviously “DNA ladder” which was the character of apoptosis, and the apoptosis index was also reduced [COA+Los: (5.
49±0.
45)% vs COA+Vehicle: (9.
62±0.
51)%, p<0.
05] with a lower express of Bax/Bcl-2 gene [COA+Los: (109.
58±7.
53)% vs COA+Vehicle: (136.
76±8.
82)%, p<0.
05] and a higher protein expression of p-Akt[COA+Los: (70.
80±6.
40)% vs COA+Vehicle: (50.
30±4.
80)%, p<0.
05].
Conclusion
Losartan might inhibit cardiomyocyte apoptosis and improve cardiac function in aortic banded rats by blocking Ang II to bind AT1-R and promoting the activation of Akt.
Conclusion
Los attenuated ventricular remodelling and improve cardiac function in aortic banded rats by blocking angiotensin II to bind AT1-R and reducing angiotensin II, aldosterone and inflammatory cytokine in myocardium.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Losartan Monotherapy vs Combination Regimens in IgA Nephropathy: A Systematic Review and Network Meta-analysis
Losartan Monotherapy vs Combination Regimens in IgA Nephropathy: A Systematic Review and Network Meta-analysis
Background: IgA nephropathy (IgAN) is a disorder in which Immunoglobulin A (IgA) antibodies build up, causing kidney damage. Losartan, an Angiotensin Receptor Blocker (ARB), has sh...
e0559 Effects of long-term right ventricular apical pacing on left ventricular remodelling and cardiac function
e0559 Effects of long-term right ventricular apical pacing on left ventricular remodelling and cardiac function
Objectives
To investigate the impacts of long-term right ventricular apical pacing on the ventricular remodelling and cardiac functions of patients with high-grad...
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival
Insulin resistance (IR) and diabetes increase the risk of acute myocardial infarction (MI). Angiotensin receptor blockers (ARBs) have been shown to reduce the risk of cardiovascula...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Blood pressure, hypertension, and the risk of aortic aneurysm in the UK Biobank
Blood pressure, hypertension, and the risk of aortic aneurysm in the UK Biobank
Abstract
Background
Although an association between elevated blood pressure and risk of aortic aneurysm is established, f...
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
Background: Candesartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker (ARB). Several clinical trials have compared candesartan with losartan in t...
Evaluation of Losartan Usage in a Regional Hospital in Hong Kong
Evaluation of Losartan Usage in a Regional Hospital in Hong Kong
Objective: To determine whether losartan usage follows the hospital's guidelines in terms of indications and reasons for use and to assess the accuracy of physicians in completing ...

